Agenus has been granted a patent for antibodies targeting TIM-3 to treat subjects. The patent includes nucleic acids, expression vectors, and host cells for antibody production. Claim 1 specifies amino acid sequences for heavy and light chain variable regions. GlobalData’s report on Agenus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agenus, Personalized cancer vaccines was a key innovation area identified from patents. Agenus's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibodies targeting tim-3 for treating subjects
A recently granted patent (Publication Number: US11839653B2) discloses an isolated polynucleotide encoding a heavy chain variable region (VH) and/or a light chain variable region (VL) of an antibody. The polynucleotide comprises specific amino acid sequences for complementarity determining regions CDRH1, CDRH2, and CDRH3 in the VH, as well as CDRL1, CDRL2, and CDRL3 in the VL. The patent claims cover various combinations of amino acid sequences for the VH and VL regions, with a focus on sequences that are at least 75% identical to specific reference sequences.
Furthermore, the patent includes claims related to vectors containing the polynucleotide sequences, host cells engineered to express the polynucleotides, and methods for producing antibodies by culturing these host cells. The patent emphasizes the importance of specific amino acid sequences in the VH and VL regions for the production of antibodies. By providing detailed sequences and combinations thereof, the patent aims to enable the efficient production of antibodies with desired properties. Overall, the patent's claims cover a range of polynucleotide sequences, vectors, host cells, and methods related to antibody production, highlighting the significance of precise amino acid sequences in the VH and VL regions for therapeutic antibody development.
To know more about GlobalData’s detailed insights on Agenus, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
